Printer Friendly

CARTHY JOINS VERTEX AS DIRECTOR OF BUSINESS DEVELOPMENT

 CARTHY JOINS VERTEX AS DIRECTOR OF BUSINESS DEVELOPMENT
 CAMBRIDGE, Mass., Feb. 25 /PRNewswire/ -- Mark Carthy has joined Vertex Pharmaceuticals (NASDAQ: VRTX) in the newly created position of director of business development. Carthy joins Vertex from Millipore, Inc., where he managed the company's worldwide chemical filtration business.
 "Carthy brings extensive experience in forging business alliances and in commercializing new technologies," said Richard Aldrich, Vertex vice president of business development. "We look forward to his contributions in strategic planning and to our efforts to establish collaborations with corporate partners in our pharmaceutical discovery programs."
 Prior to joining Millipore, Carthy was a member of the mergers and acquisitions department at Shearson Lehman Hutton. Carthy holds a masters degree in chemical engineering and a masters in business administration from Harvard Business School.
 Vertex is a leader in the use of structure-based rational drug design, a scientific approach to drug discovery through which synthetic compounds are designed at the atomic level to interact with protein targets associated with particular disease processes. Vertex applies this approach, involving the integration of advanced biology, chemistry, and biophysics to create novel, small molecule compounds, with the goal of developing these compounds into orally deliverable drugs to treat major diseases. The company is focusing on three major therapeutic areas: immunology, antiviral chemotherapy, and inflamation. Vertex's goal is to become a fully integrated pharmaceutical firm by exploiting the advantages of rational drug design in the discovery and development of novel drugs.
 -0- 2/25/92
 /CONTACT: Rich Aldrich of Vertex, 617-576-3111, or Robert Gottlieb of Feinstein Partners Inc., 617-577-8110, for Vertex/
 (VRTX) CO: Vertex Pharmaceuticals INc. ST: Massachusetts IN: MTC SU: PER


TM-SH -- NE003 -- 2273 02/25/92 10:52 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 25, 1992
Words:280
Previous Article:DEERE REPORTS FIRST QUARTER RESULTS
Next Article:LAWYERS TITLE CORPORATION REPORTS RESULTS
Topics:


Related Articles
HECTOR J. GOMEZ, M.D., PH.D., JOINS VERTEX AS VP MEDICAL AFFAIRS
STEPHANIE MARRUS JOINS VERTEX AS DIRECTOR OF CORPORATE COMMUNICATIONS
VICKI SATO TO HEAD RESEARCH AT VERTEX PHARMACEUTICALS
ROBERT SCHOOLEY, M.D., JOINS VERTEX SCIENTIFIC ADVISORY BOARD
LYNNE H. BRUM JOINS VERTEX PHARMACEUTICALS AS DIRECTOR OF CORPORATE COMMUNICATIONS
VERTEX NAMES IAIN BUCHANAN TO VICE PRESIDENT OF EUROPEAN OPERATIONS; OPENS EUROPEAN OFFICE
VERTEX PHARMACEUTICALS APPOINTS BART HENDERSON DIRECTOR OF MARKETING
James P. Feeney Joins Vertex Pharmaceuticals as Senior Director of Business Development
John J. Alam, M.D. Joins Vertex as Vice President, Clinical Development
Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters